A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in K

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Obert

Codi protocol: 299AR301
Codi EudraCT: No aplica
Grup de recerca: Nefrologia i Trasplantament Renal
Servei: Nefrologia
Investigador/a principal: Bestard Matamoros, Oriol
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III